Zobrazeno 1 - 10
of 4 793
pro vyhledávání: '"relapsed/refractory"'
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 2967-2979 (2024)
Honggang Guo,1,* Yabin Cui,2,* Yanliang Bai,1 Fan Yan,1 Wenhui Zhang,1 Yuqing Chen,1,* Mingyue Shi1,* 1Department of Hematology, Zhengzhou University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, People’s
Externí odkaz:
https://doaj.org/article/ef942d27645540179a2a8b66e4e2a8d0
Autor:
Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-11 (2024)
Abstract Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain
Externí odkaz:
https://doaj.org/article/681de79c8e1349a19906516ee568e2af
Autor:
Paula Rodriguez-Otero, Thomas Martin
Publikováno v:
Hemato, Vol 5, Iss 2, Pp 171-179 (2024)
The treatment of relapsed and refractory multiple myeloma has improved substantially in the last 5–10 years based on the development and use of several novel classes of drugs and drug combinations. These advances have led to improvements in progres
Externí odkaz:
https://doaj.org/article/f1fcc3e73eef4e409a17047281c1673a
Publikováno v:
Journal of Blood Medicine, Vol Volume 15, Pp 239-254 (2024)
Juan-Manuel Sancho,1 Marc Sorigué,1 Eva Rubio-Azpeitia2 1Clinical Hematology Department, ICO-IJC-Hospital Germans Trias I Pujol. Badalona, Universitat Autònoma de Barcelona, Barcelona, Spain; 2Medical Department-Hematology, Janssen-Cilag, S.A, Madr
Externí odkaz:
https://doaj.org/article/e8a33aab574b4bf8b9e5e60a9c8b724f
Autor:
Yuhan Ma, Hongyuan Zhou, Jiaoli Zhang, Qing Zhang, Yujie Li, Ruiyang Xie, Bingpei Zhang, Ziyuan Shen, Ping Li, Aibin Liang, Keshu Zhou, Lu Han, Yongxian Hu, Kailin Xu, Wei Sang, Xiangmin Wang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundChimeric antigen receptor T-cell (CAR-T) therapy has offered new opportunities for patients with relapsed/refractory B-cell lymphoblastic leukemia (r/r B-ALL). However, cytokine release syndrome (CRS) and immune effector cell–associated n
Externí odkaz:
https://doaj.org/article/dc38e97ee33a4778844cb1f8c26c8343
Autor:
Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the
Externí odkaz:
https://doaj.org/article/613627563fa145bcad4718e937c66eed
Autor:
Guang‐Liang Chen, Kai Xue, Qunling Zhang, Zu‐guang Xia, Jia Jin, Ran Li, Yizhen Liu, Fangfang Lv, Xiaonan Hong, Xiaoqiu Li, Junning Cao
Publikováno v:
Cancer Medicine, Vol 13, Iss 16, Pp n/a-n/a (2024)
Abstract Background In relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), a negative prognosis is frequently linked to heightened epigenetic heterogeneity. Chidamide, a selective histone deacetylase inhibitor, shows promise as a targe
Externí odkaz:
https://doaj.org/article/2ad1fa44c0184b318107224eea500a7a
Autor:
Yuankai Shi, Keshu Zhou, Hui Zhou, Yan Qin, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang, Yongping Song, Jinjin Liang, Min Wei
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102702- (2024)
Summary: Background: MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, with a nearly completely afucosylated N-glycans in Fc region, has demonstrated superior activity compared with rituximab and obinutuzumab in vitro and in vivo
Externí odkaz:
https://doaj.org/article/2a3c6df3d77e4c00af3f193cded6e60d
Autor:
Reza Mirfakhraie, Bentolhoda Kuhestani Dehaghi, Mahmoud Dehghani Ghorbi, Haniyeh Ghaffari-Nazari, Mozhdeh Mohammadian, Maryam Salimi, Maria Tavakoli Ardakani, Sayeh Parkhideh
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss 2, Pp 192-200 (2024)
Introduction: B cell acute lymphoblastic leukemia-lymphoma (B-ALL) accounts for approximately 75% of ALL cases and is observed in children and adults. Recent advances in disease diagnosis, stratification and prognostication have led to a better chara
Externí odkaz:
https://doaj.org/article/f5fea2b7b45d4045a44724e2900bea8c
Autor:
Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M. Schecter, Patricia Cost, Lida Pacaud, Abbey Poirier, Gabriel Tremblay, Tommy Lan, Satish Valluri, Shaji Kumar
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Objectives The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among patients with relapsed/refractory multiple myeloma (RRMM) base
Externí odkaz:
https://doaj.org/article/0585a86fa1414c2e9c7c39d6be67cf00